What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Diabetes mellitus
- Type 2 diabetes
John B. Buse mainly investigates Diabetes mellitus, Type 2 diabetes, Internal medicine, Endocrinology and Intensive care medicine.
The various areas that John B. Buse examines in his Diabetes mellitus study include Family medicine and MEDLINE.
His Type 2 diabetes research is multidisciplinary, incorporating perspectives in Placebo, Randomized controlled trial, Surgery and Glycemic.
His Internal medicine research incorporates elements of Liraglutide and Type 1 diabetes.
His Endocrinology study combines topics in areas such as Gastroenterology and Adverse effect.
His research in Intensive care medicine intersects with topics in Clinical trial, Obesity, Insulin resistance, Pathology and Glucose test.
His most cited work include:
- Effects of intensive glucose lowering in type 2 diabetes (5877 citations)
- Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (3586 citations)
- Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A Consensus Statement of the American Diabetes Association and the European Association for the Study of Diabetes (3465 citations)
What are the main themes of his work throughout his whole career to date?
His primary areas of study are Internal medicine, Diabetes mellitus, Type 2 diabetes, Endocrinology and Insulin.
His study in Internal medicine is interdisciplinary in nature, drawing from both Liraglutide and Placebo.
His Diabetes mellitus study incorporates themes from Surgery and Intensive care medicine.
His Type 2 diabetes research includes elements of Metformin, Clinical trial and Disease.
Postprandial and Insulin resistance are subfields of Endocrinology in which his conducts study.
John B. Buse has included themes like Proportional hazards model and Myocardial infarction in his Hazard ratio study.
He most often published in these fields:
- Internal medicine (63.67%)
- Diabetes mellitus (56.06%)
- Type 2 diabetes (43.77%)
What were the highlights of his more recent work (between 2018-2021)?
- Internal medicine (63.67%)
- Type 2 diabetes (43.77%)
- Diabetes mellitus (56.06%)
In recent papers he was focusing on the following fields of study:
Internal medicine, Type 2 diabetes, Diabetes mellitus, Insulin and Placebo are his primary areas of study.
He combines subjects such as Liraglutide, Semaglutide and Gastroenterology with his study of Internal medicine.
His Type 2 diabetes research also works with subjects such as
- Disease and related Cohort,
- Intensive care medicine which is related to area like MEDLINE.
His Diabetes mellitus research focuses on subjects like Randomized controlled trial, which are linked to Discontinuation.
John B. Buse focuses mostly in the field of Insulin, narrowing it down to matters related to Drug delivery and, in some cases, Pharmacology and Blood sugar regulation.
His Placebo study integrates concerns from other disciplines, such as Exenatide and Adverse effect.
Between 2018 and 2021, his most popular works were:
- Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (639 citations)
- International consensus on risk management of diabetic ketoacidosis in patients with type 1 diabetes treated with sodium-glucose cotransporter (SGLT) inhibitors (96 citations)
- Erratum. 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2020;43:487-493. (71 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Diabetes mellitus
- Type 2 diabetes
His scientific interests lie mostly in Internal medicine, Diabetes mellitus, Type 2 diabetes, Insulin and Randomized controlled trial.
His Internal medicine research integrates issues from Placebo and Semaglutide.
His Glycated hemoglobin study in the realm of Diabetes mellitus interacts with subjects such as Association.
His biological study focuses on Liraglutide.
The various areas that John B. Buse examines in his Insulin study include Drug delivery, In vivo and Pharmacology.
His Randomized controlled trial research focuses on Gastroenterology and how it relates to Metformin.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
